# Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

> **NCT02313012** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 19 (actual)

## Conditions studied

- Neoplasm Metastasis

## Interventions

- **DRUG:** CC-90003

## Key facts

- **NCT ID:** NCT02313012
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01-05
- **Primary completion:** 2016-05-03
- **Final completion:** 2016-05-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02313012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02313012, "Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02313012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*